Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04595474 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study completion date: Dec 30, 2025 to Dec 30, 2026v8
  2. Study completion date: Dec 30, 2024 to Dec 30, 2025v7
  3. Study completion date: Nov 30, 2023 to Dec 30, 2024v6
  4. Study completion date: Nov 30, 2022 to Nov 30, 2023v5
  5. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Jul 2022 to Aug 19, 2022
    • Study completion date: Jul 2022 to Nov 30, 2022
    • Site details revised
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Re-verified, no change to tracked fieldsv3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 2020 to Jan 14, 2021
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive imaging and serum-based methods with the goal of identifying high-risk patients with advanced fibrosis who should be prioritized for specialty referral
Trial Details
NCT Number NCT04595474
Lead Sponsor Joslin Diabetes Center
Conditions
(from sponsor)		 Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fibrosis, Liver, Type 1 Diabetes, Cirrhosis, Liver
Related terms Diabetes Mellitus, Type 1, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease
Enrollment 533 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov